InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,532.05
(
0.42%
)
US TECH 100
19,619.20
(
0.72%
)
Dow Jones
39,271.27
(
-0.15%
)
Brent Oil
86.16
(
-0.33%
)
Bitcoin
60,542.94
(
-2.39%
)
Post# of 252471
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: DewDiligence post# 94806

Tuesday, 04/27/2010 11:38:06 AM

Tuesday, April 27, 2010 11:38:06 AM

Post# of 252471
I think that Aricept does not have Hatch-Waxman data exclusivity protection anymore. Teva filed ANDA on Oct, 2004, with Para IV certification against ‘864, ‘321, ‘911, ‘760 and Para III against patent ‘841. Later, in Oct, 2005, Teva amended it’s ANDA with Para IV against patent ‘841 (the only one that Eisai is defending). Due to Para IV filing against product patent, Teva also got First Filer status.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up